OR-GUROBI-OPTIMIZATION
18.8.2020 15:02:14 CEST | Business Wire | Press release
Gurobi Optimization, LLC and River Logic, Inc today announced that River Logic has chosen the Gurobi Optimizer as the preferred mathematical optimization solver for its prescriptive analytics platform. By embedding the Gurobi Optimizer in its platform, River Logic expects its customers to take full advantage of the capabilities of this best-of-breed solver, leading in many cases to faster solve times and increased profit opportunities.
After a thorough evaluation and selection process, River Logic – which had been using another commercial solver as a component of its prescriptive analytics platform for many years – decided to switch to the Gurobi Optimizer.
River Logic’s Chief Technology Officer Peter Bull said: "We are tremendously excited to announce a long-term partnership with Gurobi to harness the power of their optimization solver technology with River Logic’s unique prescriptive analytics cloud SaaS application. River Logic, now together with Gurobi, is at the forefront of driving prescriptive analytics solutions across an increasing number of industries and organizations, helping them to transform their business operations and capabilities."
There were three main reasons behind River Logic’s decision to switch to the Gurobi Optimizer:
- Performance : The Gurobi Optimizer is the world’s fastest and most powerful mathematical optimization solver, which is constantly setting new industry standards in terms of speed and solution quality. With the Gurobi Optimizer as a key component of River Logic’s solutions, River Logic customers – many of whom are business users without a background in mathematical programming – will see a substantial reduction in the time it takes to optimally solve complex business problems.
- Vision : Gurobi’s R&D team – which is comprised of the leading experts in the mathematical optimization software industry – is fully focused on developing and delivering the best mathematical optimization solver technology. This goes hand-in-hand with River Logic’s commitment to providing the best planning and decision-support solutions to its global customers. With Gurobi and River Logic’s commitment to continuous improvement and cutting-edge innovation, River Logic customers can be assured that they are using the state-of-the-art solver – today and in the future.
- Support : Gurobi’s Support team – which is made up of PhD-level mathematical optimization specialists – is dedicated to providing world-class support for customers using the Gurobi Optimizer. River Logic’s technical team and customers will have access to Gurobi’s Support team – who will be there to assist them and make sure they are able to utilize mathematical optimization as effectively as possible in River Logic’s platform.
Gurobi’s Chief Revenue Officer Duke Perrucci commented: “We are thrilled to have the Gurobi Optimizer power River Logic's suite of first-class optimization applications. Our relentless focus on innovation will allow River Logic's customers to tackle the world's most complex problems at speed and with confidence.”
About Gurobi Optimization
Gurobi produces the world’s fastest and most powerful mathematical optimization solver – the Gurobi Optimizer – which is used by leading global companies across more than 40 different industries to rapidly solve their complex, real-world problems and make automated decisions that optimize their efficiency and profitability.
As the market leader in mathematical optimization software, we aim to deliver not only the best solver, but also the best support – so that companies can fully leverage the power of mathematical optimization (on its own or in combination with other AI techniques such as machine learning) to drive optimal business decisions and outcomes.
Founded in 2008, Gurobi has operations across the USA, Europe, and Asia and has more than 2,500 customers globally including SAP, Air France, Uber, and the National Football League (NFL). For more information, please visit www.gurobi.com or call +1 713 871 9341.
About River Logic
River Logic is on a mission to ensure companies across the globe drive maximum value with every decision, no matter how complex the business problem or how quickly markets shift. As a global innovator in advanced analytics, River Logic offers optimization solutions purpose-built for business users rather than data scientists. Its cloud-based solutions enable enterprise-wide optimization through a revolutionary cloud experience that offers rapid scenario collaboration, data management, workflows, scalability, and more. Companies are finally able to align decisions around complex trade-offs with overarching business objectives without sacrificing speed, agility, and flexibility. For more information, please visit www.riverlogic.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200818005265/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
